Latest Hotspot

KalVista Seeks FDA Approval for Sebetralstat, First Oral Treatment for Hereditary Angioedema

21 June 2024
3 min read

KalVista Pharmaceuticals, Inc. has disclosed that they have filed a New Drug Application with the U.S. Food and Drug Administration for the evaluation of sebetralstat. This innovative investigational oral plasma kallikrein inhibitor is intended for the immediate treatment of hereditary angioedema attacks in both adult and pediatric populations aged 12 and above.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

"Our NDA submission signifies a critical juncture not just for our organization, but for the entire HAE community, as we endeavor to introduce a groundbreaking therapeutic innovation through the first-ever oral, on-demand treatment for HAE," stated Ben Palleiko, Chief Executive Officer of KalVista. 

"This milestone reflects the extensive effort and dedication of the entire KalVista team, bolstered by the indispensable support from individuals living with HAE, our collaborations with the HAE scientific community, the HAEA and HAEi patient advocacy groups, regulators, and other stakeholders. This underscores our unwavering commitment to addressing the persistent unmet needs of those afflicted by this rare condition. Should approval be granted, we anticipate that sebetralstat could serve as a cornerstone therapy that will revolutionize the way HAE is managed," Palleiko continued.

The NDA submission is grounded in previously reported clinical trial outcomes, notably data from the KONFIDENT phase 3 trial and the KONFIDENT-S extension trial. In the phase 3 trial, sebetralstat met the primary endpoint, with both 300 mg and 600 mg doses providing significant symptom relief more rapidly than placebo. The median time to initiation of symptom relief was shorter compared to placebo.

Aligned with earlier studies, sebetralstat exhibited a favorable safety profile, comparable to placebo, with no serious treatment-related adverse events recorded. This advantageous safety profile has been consistently observed in all clinical trials for sebetralstat up to this point.

The FDA has a 60-day review period to decide whether the NDA is complete and ready for review. KalVista expects to receive a decision from the FDA regarding the submission's status in September. The Company also plans to submit additional marketing authorization applications to other global health authorities throughout 2024.

If approved, sebetralstat would mark the first oral, on-demand therapy for individuals with HAE. The NDA submission includes patients aged 12-17 years, a demographic that faces significant challenges with injectable treatments. KalVista intends to initiate a pediatric trial in the third quarter of 2024, which, if successful, would enable future applications to extend coverage to patients aged 2-11 years.

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

According to the data provided by the Synapse Database, As of June 21, 2024, there are 28 investigational drugs for the KLKB1 targets, including 27 indications, 30 R&D institutions involved, with related clinical trials reaching 86, and as many as 3516 patents.

Sebetralstat's small molecule nature, its targeting of KLKB1, its therapeutic areas, and its regulatory status collectively position it as a promising candidate for the treatment of Hereditary Angioedema and other related conditions. As the drug continues through the development process, further clinical data will be essential in determining its ultimate impact on patient outcomes.

图形用户界面, 文本, 应用程序

描述已自动生成

Is Pretomanid approved by the FDA?
Drug Insights
4 min read
Is Pretomanid approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) granted approval for Pretomanid on August 14, 2019.
Read →
Update on Phase III CAPItello-290 Study: Truqap and Chemotherapy for Advanced Triple-Negative Breast Cancer
Latest Hotspot
3 min read
Update on Phase III CAPItello-290 Study: Truqap and Chemotherapy for Advanced Triple-Negative Breast Cancer
21 June 2024
Update on the CAPItello-290 Phase III study of Truqap combined with chemotherapy for advanced or metastatic triple-negative breast cancer.
Read →
Is Pexidartinib approved by the FDA?
Drug Insights
4 min read
Is Pexidartinib approved by the FDA?
21 June 2024
The U.S. Food and Drug Administration (FDA) approved Pexidartinib on August 2, 2019.
Read →
FDA Approves NMD Pharma's Phase 2 Trial of NMD670 for Charcot-Marie-Tooth Disease in US
Latest Hotspot
4 min read
FDA Approves NMD Pharma's Phase 2 Trial of NMD670 for Charcot-Marie-Tooth Disease in US
21 June 2024
NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.